By performing blood tests on cancer patients, it is possible to monitor the recurrence of cancer in patients with advanced melanoma skin cancer during treatment.

Research staff from the Manchester Cancer Institute in the United Kingdom conducted a study of circulating tumor DNA in blood samples from seven patients with advanced melanoma. Their findings demonstrate that cancer recurrence can be judged by tracking the level of CtDNA in the blood.

In addition, the researchers also found that if mutations such as NRAS and PI3K are detected, it is highly likely that cancer will recur in the course of cancer treatment.

Most melanoma patients have a certain therapeutic effect during the initial medical treatment. But often after a year, these tumors will appear resistant to cancer treatment. Therefore, this method of detecting CtDNA in patients can help doctors find and carry out individualized treatment for patients, and help patients get the best results in cancer treatment.

BRAF gene mutations are present in 40-50% of melanoma patients. These skin cancer patients can use the targeted drug vemurafenib or dabrafenib to treat cancer. However, these two classes of drugs are not suitable for cancer patients carrying the normal BRAF gene, or tumor resistance may occur during a short period of treatment.

If this happens, these patients can use some immunotherapeutics, such as some monoclonal antibodies: Pembrolizumab, Nivolumab, and Ipilimumab. If the patient's genetic mutation has been detected in the early stage of treatment, personal information such as medical treatment can be improved, and individualized treatment can improve the prognosis of the patient, and the survival rate and quality of life of the patient can be improved.

Richard MaraisB, a skin cancer specialist from the Cancer Research Center, said: "If we can find signs of recurrence of skin cancer as early as possible, we can quickly develop an optimal individualized treatment plan. It is worth investigating and developing new ones. Detection technology. Through our detection technology, we hope to find the recurrence of cancer at the earliest time, start a new treatment plan as soon as possible. Get more time for patients to accompany their loved ones. Although our current work has found a specific Direction, but before entering clinical trials, more preclinical experiments are needed to validate the technology."

ELISA Analyzer

Processing high-throughput samples, intelligent reuse for large-capacity publishing, work surface: 200cm, 8 sample injection needles, 12 temperature-controlled incubation positions, 12 room temperature incubation positions, 32 plate storage positions, Sunrise microplate reader, HydroFlex plate washer, up to 512 specimens, sequential loading of samples, reagents, microplates Parallel loading of up to 6 plates for fast dispensing.

The automatic enzyme immunoassay analyzer is based on the principle that the enzyme and the substrate can produce a color reaction, the absorption lines of different substances have different characteristics, and strictly abide by the Lambert-Beer law, quantitative and qualitative analysis of substances. instrument. The method of analyzing the content of various enzymes such as antigen or antibody generally mainly adopts colorimetric method. In practice, spectrophotometry is the basic working principle of an automatic enzyme immunoassay analyzer. The light emitted by the light source lamp becomes a beam of monochromatic light after passing through a filter or a monochromator. The monochromatic light beam passes through the sample to be tested in the microtiter plate, and part of the monochromatic light beam is absorbed by the sample and reaches the photodetector. The intensity of the light signal projected on it is converted into the magnitude of the electrical signal by the photodetector. This electrical signal is processed by pre-amplification, logarithmic amplification, analog-to-digital conversion, etc., and then sent to the microprocessor for data processing and calculation, and the test results are output by the display and printer. The microprocessor completes the movement in the X and Y directions of the mechanical drive through the control circuit.
The automatic enzyme immunoassay analyzer adds the sample to the microwells of the pre-coated antigen or antibody microtiter plate, washes after the reaction, removes the unseparated ligand, then adds the enzyme isolate, after incubation, washes again , remove the unseparated compound, and then add the enzyme substrate, after the reaction, the colored final product is formed, and the stop solution is added to stop the reaction. The absorbance of each microwell of the microtiter plate is read by the wavelength that has been set by the spectrophotometer. The concentration value of the analyte in the sample is calculated by the absorbance value of the sample and the standard curve, so that the quantitative result can be obtained, or the absorbance of the sample is compared with that of the standard product, so that the positive or negative qualitative result can be obtained.

ELISA analyzer,enzyme immunoassay workstation,automatic enzyme immunoassay analyzer,automatic enzyme immunoassay system

Jilin Sinoscience Technology Co. LTD , https://www.jilinsinoscience.com